Interim report Q1 2023
Copenhagen, Denmark, 25 May 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the interim report Q1 2023. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.Curasight’s CEO Ulrich Krasilnikoff comments: “During the first quarter of 2023, we continued to make progress with our updated clinical strategy as well as pursuing our partnership strategy, as part of our efforts to build a strong theranostics business focused on improving cancer treatments with more accurate diagnosis